Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ: BCRX ) with a Overweight and raises the price target from $27 to $29.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.